The development of effective
therapies for the prevention of
colorectal cancer (CRC) liver
metastasis is of great importance. Recently,
chitosan (CS) nanoparticles have been utilized as carriers of interluekin-12 (IL-12) administered locally to deliver therapeutic
proteins and genes. In this study, we encapsulated
IL-12 by incorporation using
tripolyphosphate (TPP) as the coacervated crosslinking agent to form CS-TPP/
IL-12 nanoparticles. We further characterized the association efficiency, rate of release, liver-targeting, and toxicity, which were predominantly dependent on the factors of particle size, zeta potential, pH of
solution, and whether or not modified with TPP. Systemic delivery of CS-TPP/
IL-12 nanoparticles significantly reduced the number and volume of CRC liver
metastasis foci compared to the CS-TPP treated mouse group. Although delivery of
IL-12 alone also inhibited the number of CRC liver
metastasis observed, further study of the change in hepatic
metastasis volume demonstrated no significant differences between the groups treated with CS-TPP or
IL-12 alone. Mechanistically, CS-TPP nanoparticles blocked the toxicity of
IL-12 and induced infiltration of NK cells and some T cells, which are most likely the effector cells that mediate
tumor metastasis inhibition during CS-TPP/
IL-12 immunotherapy. The results obtained from this study demonstrate the potential benefit of using
chitosan modification technology as a
cytokine delivery system for the successful prevention of CRC liver
metastasis by exploiting liver immunity.